Ibogaine and traumatic brain injury

Searches for ibogaine and brain injury have grown quickly, and the reason is a single study. In 2024 a team at Stanford published findings on 30 US Special Operations Forces veterans with a history of traumatic brain injury who had travelled to a clinic in Mexico for ibogaine treatment. The reported reductions in disability and psychiatric symptoms were unusually large. A follow-up imaging paper then reported changes in brain structure. Those two papers are the whole of the substantial human evidence on this question, so what they did and did not establish is worth setting out carefully.

The headline figures are real and were published in a leading medical journal. The design behind them was observational, with no control group and no blinding, which places a firm ceiling on what can be concluded. Both things are true at once, and reporting one without the other misrepresents the work.

The question people are asking

Two quite different questions tend to get merged. The first is whether ibogaine improves the psychiatric symptoms that commonly follow repeated head injury: post-traumatic stress, depression, anxiety and functional disability. The second is whether ibogaine repairs physical damage to brain tissue. The published work speaks mainly to the first. The second remains a hypothesis, and the authors of the imaging study say so themselves.

What the study actually was

The cohort was 30 male veterans, mean age 44.9, with a history of repeated blast and combat exposure. The injury burden was heavy: a mean of 38.6 lifetime traumatic brain injuries by structured assessment, of which 28 participants were classified as mild, one moderate and one moderately severe, across a mean of 5.5 combat deployments [1]. At baseline, diagnostic interview identified post-traumatic stress disorder in 23, major depression in 15, an anxiety disorder in 14 and alcohol use disorder in 15. Nineteen had a history of suicidal ideation and seven a past attempt.

The design was prospective, observational, open label and single arm, with no control group, no blinding and no power calculation [1]. Participants arranged and self-scheduled their own treatment at a clinic in Mexico, funded by a veterans' nonprofit, between November 2021 and September 2022, and were separately referred to Stanford for assessment. Stanford played no part in the dosing. Assessments took place two to three days before treatment, four to five days after, and one month after.

The clinic's own screening was substantial: bloodwork, an electrocardiogram, and withdrawal of a long list of medications beforehand, including CYP2D6 inhibitors, serotonergic drugs, calcium channel blockers, beta blockers, benzodiazepines, stimulants, corticosteroids and all psychiatric medication. Exclusions covered cardiovascular, liver and kidney history, psychosis and neurological disorder. Intravenous magnesium sulfate was given before dosing and again afterwards, an addition intended to reduce cardiac risk [1].

Those details matter for interpretation. The participants were a selected, highly motivated group who had stopped their existing psychiatric medications, travelled internationally, and received intensive attention over several days. Any of those factors could contribute to an improvement in self-reported and clinician-rated symptoms.

The symptom results

The reported changes were large. Clinician-administered PTSD scores fell from 31.7 at baseline to 3.9 immediately after treatment and 4.8 at one month, effect sizes of 2.30 and 2.54. Depression scores fell from 25.6 to 2.8 and then 3.8, effect sizes of 2.65 and 2.80. Anxiety scores fell from 20.8 to 3.6 and 3.9. Suicidal ideation was present in 47 percent of participants at baseline, none immediately after treatment and 7 percent at one month. Remission rates of 83 to 86 percent were reported across the psychiatric measures, and functional disability also fell [1].

Effect sizes above 2 are far outside what established treatments for these conditions typically produce, which is part of why the study attracted attention. It is also a reason for caution rather than confidence, because uncontrolled designs tend to inflate apparent effects, and the larger the reported effect in such a design, the more the design itself becomes the thing under scrutiny.

A companion qualitative paper asked the same participants to write about the experience. Four themes emerged: re-encountering and re-appraising traumatic memories, often accompanied by forgiveness and acceptance; an observer-like or dissolved sense of self; emotional resolution; and bodily sensations that participants interpreted as their brain healing [5]. The authors are explicit that they treat the last of these as an embodied metaphor rather than evidence of literal repair, a distinction that has frequently been lost in secondary coverage.

A further analysis found that participants who reported a more intense mystical experience during treatment showed larger PTSD reductions, both immediately and at one month [4]. That is an association within a single uncontrolled cohort, not a demonstration that the experience causes the improvement, and it is equally consistent with both reflecting a third factor such as expectancy or engagement.

What the brain imaging showed

Structural MRI scans were obtained from the same cohort at baseline, immediately after treatment and at one month, with 25, 25 and 22 usable scans respectively. Cortical thickness increased in 11 regions and there was subcortical expansion in 8 regions. A machine-learning estimate of brain age, derived from the scans, fell by a mean of about 1.3 years at one month compared with baseline [2].

The authors attach substantial caveats to their own result. They caution that the brain-age figure should not be read as brains becoming younger. They note that the T1-weighted scans used are sensitive to changes that are not structural at all, including hydration and blood flow, which can shift measured thickness without any change in tissue. They also observe that lifestyle changes following a strongly felt treatment experience could in principle affect brain structure, meaning the imaging change need not be a direct pharmacological effect [2].

Read within those limits, the imaging is a genuine finding that justifies further study and does not establish tissue repair. There was no control group scanned over the same interval, so normal variation and measurement drift cannot be ruled out.

What happened at twelve months

A longer follow-up of the same cohort reports that the improvements held. Twenty-five of the 30 participants completed assessment at 12 months, with effect sizes at or above 2.18, and estimated probabilities of sustained remission at 12 months of 84 percent for PTSD, 66 percent for depression and 61 percent for anxiety [3].

That report is a preprint and has not completed peer review, with a journal decision to revise recorded in February 2026 [3]. It should be read as provisional. Durability over a year, if it survives review, would be a meaningful addition, because short-lived improvement is a common pattern in open-label psychiatric research and a 12-month signal is harder to explain by immediate expectancy alone. It still carries the same absence of a comparison group.

What the study cannot show

Without a control group, the study cannot separate the effect of ibogaine from several other influences acting at the same time. Participants knew what they were taking. They had stopped psychiatric medications, which alters symptom scores by itself. They had invested effort and expectation in travelling for treatment. They received days of close attention in a therapeutic setting. Each of those plausibly moves the measures that were used, and the design provides no way to apportion the change.

Running the controlled trial that would settle this is harder than it sounds. A full ibogaine dose is unmistakable to the person receiving it, which means participants in any placebo-controlled design can generally tell which arm they are in. A 2026 review of novel treatments for opioid use disorder names exactly this problem, noting that perceptible drug effects tend to unblind allocation, and argues that trials in this area need active comparators, formal blinding checks and endpoints that do not depend on the participant's own report [8]. For an outcome like PTSD severity, which is assessed through interview, that is a substantial design obstacle rather than a technicality.

Nor would a single trial be enough on its own. The MISTIC cohort was recruited through a veterans' nonprofit and consisted of men who had already decided to seek ibogaine abroad, which is a narrow slice of the population that might eventually be offered such a treatment. Replication in a cohort that did not select itself, with a comparison group assessed on the same schedule, is the step that would turn a striking observation into usable clinical evidence.

The broader literature says the same thing in general terms. A 2026 review of three decades of human ibogaine research concluded that most positive efficacy data come from uncontrolled, open-label or retrospective studies, many conducted in nonclinical settings and at high risk of bias [6], and a 2019 pharmacology review had already noted that the human effects reported for ibogaine were found mainly in uncontrolled clinical trials and observational studies [7].

Repair and symptoms are different claims

The distinction worth holding on to is this. The MISTIC cohort was defined by a history of traumatic brain injury, and what was measured was psychiatric symptoms and self-rated function in people with that history. Improvement on those measures is not the same as improvement in the injury. A person can have persistent structural damage and markedly less post-traumatic stress, and that is a worthwhile outcome described accurately. Describing it as brain repair claims something the data do not contain, and the imaging paper's own authors decline to make that claim [2].

Nothing in this evidence addresses acute head injury, nor does it support ibogaine as a treatment for the cognitive consequences of injury, which were not the primary outcomes. The honest summary is that one selected cohort with a heavy injury history reported large and apparently durable psychiatric improvement after ibogaine, that structural imaging changed in a direction consistent with that, and that a controlled trial capable of attributing that improvement to the drug itself has not yet been done.

None of that makes the finding uninteresting. A cohort with this injury burden and these baseline diagnoses would not ordinarily be expected to show remission rates above 80 percent on any measure, and the result is striking enough that the absence of a controlled replication is now the most important open question in the field rather than a footnote to it.

Frequently asked questions

Does ibogaine repair brain damage?

That has not been shown. Cortical thickness rose in 11 regions and an estimated brain age fell by about 1.3 years in one uncontrolled cohort, but the authors warn against reading the brain-age figure literally and note that the scans used are sensitive to non-structural change [2].

Was the Stanford study a clinical trial?

Not in the controlled sense. It was prospective and observational, open label, single arm, with no control group, no blinding and no power calculation, and the treatment itself took place at a clinic in Mexico that the participants arranged independently [1].

Do the benefits last?

A preprint following the same cohort reports that they held at 12 months in 25 of 30 participants, with sustained remission estimated at 84 percent for PTSD [3]. That report has not completed peer review and should be treated as provisional.

Would these results apply to a civilian with one concussion?

There is no evidence either way. The cohort was male special operations veterans with a mean of 38.6 lifetime injuries and high rates of PTSD, depression and alcohol use disorder [1]. A different population with a different injury history is not represented in the data.